Back

Additive benefits of combination ARNI and SGLT2 inhibitor therapy in real-world heart failure: a propensity-weighted analysis of 11,483 asian patients

28 August 2026 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Heart failure: integrating therapies and education Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Porntep Amornritvanich

Police General Hospital, Bangkok (Thailand)

6 More presentations in this session

Presentation thumbnail
Low blood pressure and the effect of SGLT2 inhibitors in heart failure with reduced ejection fraction: data from the China Cardiovascular Association Database-Heart Failure Center Registry
Doctor W. Jin (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Hyperkalemia and its outcome implications in patients with heart failure with reduced ejection fraction: results from a single-center cohort
Doctor M. Mantovani (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Efficacy of sodium–glucose cotransporter 2 inhibitors in heart failure patients with low body mass index
Doctor K. Nakamoto (Osaka, JP)
Abstract Slides Video
Presentation thumbnail
Outcomes of sacubitril/valsartan plus SGLT2 inhibitors versus SGLT2 inhibitors in heart failure with reduced ejection fraction: a propensity-matched real-world analysis
Doctor O. Alameen (Doha, QA)
Abstract Slides Video
Presentation thumbnail
Systematic review and meta-analysis of GLP-1 receptor agonists in heart failure: impact on 6-minute walk test performance
Doctor T. Christophides (Nicosia, CY)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure: integrating therapies and education

The Event

Event poster

ESC Congress 2026

28 August 2026 11:15 CET
You may be interested in
thumbnail
Congress Session
Pharmacotherapy
23 May 2023
thumbnail
Congress Presentation
Effect of sacubitril/valsartan and SGLT2 inhibitors on echocardiographic response and clinical outcomes after cardiac resynchronization therapy: insights from a real-world cohort
10 May 2026
thumbnail
Congress Presentation
Sodium-glucose co-transporter-2 inhibitors: prognostic benefit in real-world, elderly, comorbid HFmrEF and HFpEF patients
19 May 2025
thumbnail
Congress Presentation
Real-world comparison between ARNI and RAS Blockade in Patients with HFrEF
22 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources